Millie Das is an Oncology physician affiliated with VA Palo Alto Health Care System. OpenAlex indexes 143 publications with 2,361 citations (h-index 24).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
300 Pasteur Dr
Palo Alto, CA 943042203
Telephone
650-723-4000Provider last certified this registry record 28 Apr 2024.
Industry payments
26 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- JAZZ PHARMACEUTICALS INC.Program year202513 payments$14,239openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year202510 payments
- Eli Lilly and CompanyProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor100%Tagrisso100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma
Nature Communications
2025 - UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas
Cell Reports Medicine
2024 - Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update
Journal of Clinical Oncology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
David Relman, MD
VA Palo Alto Health Care System
Ramsey Cheung, MD
VA Palo Alto Health Care System
Arden Morris, MD
VA Palo Alto Health Care System
Odette Harris, MD
VA Palo Alto Health Care System
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”